Efgartigimod Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Efgartigimod Alfa. Educational only — not medical advice.
Labeled uses
VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP)
Source: FDA labeling via NIH DailyMed (set 7104d9e5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.